Online ISSN: 3007-0244,
Print ISSN:  2410-4280
SUMMARY RISTOCETINUM FOR ANALYSIS OF VON WILLEBRAND FACTOR: DO WE ACTUALLY NEED IT?
Author(s): Kastaman K.
Ristocetinum – cofactor analysis (R:Co) is the main method for estimation of von Willebrand factor activity at diagnostic of Willebrand diseases (WD). Nevertheless, this analysis is distinct with bad reproducibility and low sensibility at low rates of FWV and it is considerably time-consuming. In this paper, Lawrie and coauthor have evaluated the productivity of new immuno-turbidimetric analysis to define activity of FWV (INNOVANCE® VWF Ac., Siemens Healthcare Diagnostics, Marburg, Germany). In this analysis ristocetinum and thrombocytes are not use and changed with fragment of recombinant glycoprotein of thrombocytes lb (GPlb) with affectedly impregnate mutations ameliorative fixation FWV and GPlp. There were use 50 standard control samples, blood samples of 80 WD patients and 50 with erythrocatalysis, icterus and hiperlipoidemia evidences which were compared with data of classic FWV:RCo test, rest on thrombocytes. Results correlation of FWV:RCo was satisfactory as well as calculated quotient of FWV:Ac and FWV:RCo to FWV:Aг. Nonetheless, detection limit of FWV:Ac was lower than FWV:RCo (3cl/lg and 5cl/lg) properly. Authors reason that new analysis is sure and more sensitive than FWV:RCo at low concentration of FWV. Analysis is simple and less difficult for carrying out at unspecialized laboratories.
К. Кастаман Резюме и комментарии Центр гемофилии и тромбозов, Отделение клеточной терапии и гематологии, Больница Сан-Бортоло, г. Виченца, Италия
1. Macfarlane DE, Stibbe J, Kirby EP er al. A method for assaying von Wiliebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308. 2. Gangarosa EJ, Johnson TR, Ramos HS. Ristocetin-induced thrombocytopenia: site and mechanism of action. Arch Intern Med I960; 105:83-89. 3. Rodeghiero F, Castaman G. Calibration of lyophilized standards for ristocetin cofactor activity of von Willebrand Factor (vWF) requires vWF-deficient plasma as diluent for dose-response curves. Thromb Haemost 1987; 58: 978-981. 4. Lee CA, Hubbard A, Sabin CA et ah, 15th SSC Subcommittee on ФфВ. Laboratory diagnosis of von Wili-ebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. J Thromb Haemost 2011; 91: 220-222. 5. Flood VH, Gill JC, Morateck PA etal. Gain-of-function GPIb ELISA assay for ФфВ activity in the Zimmerman Pro-gram for the Molecular and Clinical Biology of VWD. Blood 2011; 117: e67-74. 6. Othman M. Platelet-type von Wiliebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost 2011; 37: 464-469. 7. Federici AB, Mannucci PM, Castaman G et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Wiliebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113: 526-534.
Number of Views: 276

Key words:

Category of articles: Experimental medicine

Bibliography link

К. Кастаман Ристоцетин для анализа фактора фон виллебранда: нужен ли он нам? // Наука и Здравоохранение. 2014.№ 2. С.20-22 K.Kastaman Hemophilia and Thrombosis Center, Department of Cellular Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy// Nauka i Zdravookhranenie. 2014.№ 2. С. 20-22 К. Кастаман Италия, Сан-Бортоло ауруханасы, гемофилия және тромбоздар орталығы, клеткалық терапия және гематология кафедрасы Викенца // Ғылым және Денсаулық сақтау 2014.№ 2. С. 20-22

Авторизируйтесь для отправки комментариев